Pathway Mutation Accumulate Perturbation Score: A prognostic and predictive biomarker for immunotherapy in advanced gastric cancer | Synapse
March 19, 2026Open Access
Pathway Mutation Accumulate Perturbation Score: A prognostic and predictive biomarker for immunotherapy in advanced gastric cancer
Key Points
To assess the PMAPscore-based risk model's effectiveness in predicting survival and immunotherapy responses in advanced gastric cancer.
Developed a risk model using PMAPscore
Analyzed survival rates in advanced gastric cancer patients
Evaluated immunotherapy response correlated with PMAPscore
PMAPscore effectively predicts survival outcomes
Improved identification of patients likely to benefit from immunotherapy
Supports clinical use for tailoring treatment strategies
Abstract
The PMAPscore-based risk model is a robust tool for predicting survival and immunotherapy responses in patients with advanced GC, supporting its clinical application for treatment stratification.